[go: up one dir, main page]

NZ560696A - Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue - Google Patents

Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue

Info

Publication number
NZ560696A
NZ560696A NZ560696A NZ56069600A NZ560696A NZ 560696 A NZ560696 A NZ 560696A NZ 560696 A NZ560696 A NZ 560696A NZ 56069600 A NZ56069600 A NZ 56069600A NZ 560696 A NZ560696 A NZ 560696A
Authority
NZ
New Zealand
Prior art keywords
epo
injury
mammal
excitable tissue
protection
Prior art date
Application number
NZ560696A
Inventor
Michael Brines
Anthony Cerami
Carla Cerami
Original Assignee
Kenneth S Warren Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S Warren Inst Inc filed Critical Kenneth S Warren Inst Inc
Publication of NZ560696A publication Critical patent/NZ560696A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is the use of erythropoietin (EPO), an EPO receptor activity modulator, an EPO-activated receptor modulator, or a combination of at least two thereof for preparing a pharmaceutical composition for the protection of a mammal from pathology resulting from injury to excitable tissue, wherein said EPO, EPO receptor activity modulator, or EPO-activated receptor modulator is capable of activating EPO receptors of excitable tissue, wherein the pharmaceutical composition is for peripheral administration in a non-toxic amount effective to achieve said protective effect, wherein the pharmaceutical composition is for administration before or after the onset of the injury, and wherein said injury is the result of Friedrich's ataxia, multiple sclerosis, amyotrophic lateral sclerosis, brain ischemia, stroke, or the result of injury to retinal tissue (such as retinal ischemia or retinal trauma).
NZ560696A 1999-04-13 2000-04-13 Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue NZ560696A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US54722000A 2000-04-11 2000-04-11

Publications (1)

Publication Number Publication Date
NZ560696A true NZ560696A (en) 2010-03-26

Family

ID=26966493

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ533098A NZ533098A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin at high doses
NZ560696A NZ560696A (en) 1999-04-13 2000-04-13 Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue
NZ514690A NZ514690A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin
NZ545478A NZ545478A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ533098A NZ533098A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin at high doses

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ514690A NZ514690A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin
NZ545478A NZ545478A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin

Country Status (21)

Country Link
EP (1) EP1171147A4 (en)
JP (1) JP2003520194A (en)
KR (2) KR100883232B1 (en)
CN (1) CN1607957B (en)
AU (1) AU784550B2 (en)
BG (1) BG65353B1 (en)
BR (1) BR0009737A (en)
CA (1) CA2383940A1 (en)
CR (1) CR6501A (en)
CZ (1) CZ20013695A3 (en)
EA (1) EA004766B1 (en)
HU (1) HUP0201598A3 (en)
IL (2) IL145895A0 (en)
IS (1) IS6104A (en)
MX (1) MXPA01010177A (en)
NO (1) NO20014991L (en)
NZ (4) NZ533098A (en)
PL (1) PL352223A1 (en)
SK (1) SK14412001A3 (en)
TR (2) TR200402194T2 (en)
WO (1) WO2000061164A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (en) 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ATE444077T1 (en) 2000-06-30 2009-10-15 Tokyo Metropolitan Inst Of Ger PREVENTIVES AND THERAPEUTICS FOR DEMYELINIZATION-ASSOCIATED DISEASES
DE10043457A1 (en) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Processes for treating schizophrenia and related psychoses, and using erythropoietin or erythropoietin derivatives to treat schizophrenia and related psychoses
PA8536201A1 (en) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
ES2284858T3 (en) * 2001-02-02 2007-11-16 Ortho-Mcneil Pharmaceutical, Inc. TREATMENT OF NEUROLOGICAL DYSFUNCTION THAT INCLUDES SULFAMATES OF FRUCTOPIRANOSE AND ERYTHROPOYETINE.
US20030118630A1 (en) * 2001-12-07 2003-06-26 Anthony Cerami Immune modulation device for use in animals
JP4583029B2 (en) 2001-10-29 2010-11-17 クルセル ホランド ベー ヴェー Method and method for producing a protein having a predetermined post-translational modification
DE60224843T2 (en) 2001-12-07 2009-01-08 Crucell Holland B.V. Production of viruses, virus and vaccines
CA2476538C (en) 2002-01-09 2012-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
DE10234192B4 (en) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Use of erythropoietin
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
AU2004226372A1 (en) * 2003-03-27 2004-10-14 Janssen Pharmaceutica N.V. Use of erythropoietin in stroke recovery
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
KR101183770B1 (en) 2003-05-09 2012-09-17 크루셀 홀란드 비.브이. Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
DE102004004509B4 (en) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AT500929B1 (en) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw PHARMACEUTICAL PREPARATION CONTAINING ERYTHROPOIETIN
KR20190084136A (en) 2005-08-05 2019-07-15 아라임 파마슈티칼즈, 인크. Tissue protective peptides and uses thereof
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
GB0525540D0 (en) * 2005-12-15 2006-01-25 Isis Innovation New treatment
DE102006004008A1 (en) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
CN101062407A (en) * 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US8133860B2 (en) * 2006-07-20 2012-03-13 Rosalind Franklin University Of Medicine And Science Facilitation of resuscitation from cardiac arrest by erythropoietin
EP2101808A4 (en) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
KR20190085187A (en) 2008-01-22 2019-07-17 아라임 파마슈티칼즈, 인크. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
RU2519695C2 (en) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Medication for treating attention deficit disorder and method of treating attention deficit disorder
CN111066727B (en) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 Method for constructing mouse model of action mechanism in permeability of hypoxic blood testis barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6197229A (en) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd Stable erythropoietin preparation
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (en) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia

Also Published As

Publication number Publication date
AU4348700A (en) 2000-11-14
WO2000061164A1 (en) 2000-10-19
KR20020000874A (en) 2002-01-05
EA004766B1 (en) 2004-08-26
NZ514690A (en) 2004-07-30
CZ20013695A3 (en) 2002-02-13
TR200103785T2 (en) 2002-06-21
HUP0201598A2 (en) 2002-09-28
NZ545478A (en) 2008-04-30
NO20014991L (en) 2001-11-15
CN1607957B (en) 2012-10-10
BG65353B1 (en) 2008-03-31
PL352223A1 (en) 2003-08-11
CA2383940A1 (en) 2000-10-19
CR6501A (en) 2004-04-15
IL145895A (en) 2010-05-31
BG106058A (en) 2002-12-29
CN1607957A (en) 2005-04-20
TR200402194T2 (en) 2004-10-21
KR101012932B1 (en) 2011-02-08
NO20014991D0 (en) 2001-10-12
KR20070094997A (en) 2007-09-27
SK14412001A3 (en) 2002-03-05
BR0009737A (en) 2003-01-14
MXPA01010177A (en) 2004-09-10
IS6104A (en) 2001-10-11
KR100883232B1 (en) 2009-02-10
HUP0201598A3 (en) 2002-10-28
JP2003520194A (en) 2003-07-02
EP1171147A1 (en) 2002-01-16
EP1171147A4 (en) 2003-05-14
NZ533098A (en) 2006-04-28
IL145895A0 (en) 2002-07-25
EA200101073A1 (en) 2002-10-31
AU784550B2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
NZ560696A (en) Use of erythropoietin based medicaments for the protection of a mammal from pathology resulting from injury to excitable tissue
IL126132A0 (en) Improved antiperspirant stick composition
MY131810A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
EP0998925A4 (en) Medicinal compositions for topical administration containing vitamin d and vitamin k
CA2054822A1 (en) Formulations and their use in the treatment of neurological diseases
CA2282427A1 (en) Controlled release of pharmaceuticals in the anterior chamber of the eye
HUT68498A (en) L-dopa ester compositions and process to prepare them
AU9671798A (en) Allosteric adenosine receptor modulators
UA26455C2 (en) MEDICINAL PRODUCT IN THE FORM OF TABLETS WITH SLOW RELEASE OF THE ACTIVE INGREDIENT
DE69034043D1 (en) PCP RECEPTOR LIGANDS AND THEIR USE
MX9603489A (en) Novel opioid peptides for the treatment of pain and use thereof.
EP1671973A3 (en) Allosteric adenosine receptor modulators
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
MY124465A (en) Reduction of infarct volume using citicoline
EP0393707A3 (en) Bioactive compounds associated with liposomes and their use in pharmaceutical preparations
ZA95150B (en) Application of riluzole in the treatment of mitochondrial diseases
TR200103144T2 (en) New compounds
HUP0102987A3 (en) Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient
CA2091134A1 (en) Therapeutic agent for threatened abortion
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
MXPA04002099A (en) Medicinal compositions for diabetic neuropathy.
MXPA01009384A (en) Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin.
PL292558A1 (en) Cosmetic agent for treating damages caused by heat and light radiation
CA2137755A1 (en) Palliation of sickle cell disorders by phenylurea, benzylurea, or phenylethylurea or by a homolog ring-substituted with one methoxyl, methyl, or hydroxyl radical

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 13 APR 2020 BY CPA GLOBAL

Effective date: 20130308

EXPY Patent expired